Sales of Wegovy affected the growing competition of external versions, says General Manager star-news.press/wp

Novo Nordiska for sale (NGO-2.01%) Blockbuster The weight loss is hit by Wegovy due to the rise of competition from the state of emergency or complex, the PHARMA Giant Director of the Pharma Giant Lars Fruergaard Jørgensen Fruergaard Jørgensen.

Growing popularity Complex semaglutide – The copy of the active ingredient in Oszzpić and Wegovy – at the annual meeting was the top of the company and the company’s executives and shareholders.

Still, Jørgensen picked up that sales of drug weight loss drugs increased 57% last year.

“We are currently treating about 1.2 million years of hospitals in the USA, while 55 million people have insurance for Wegovy,” Jørgensen said. “We continue to focus on scaling, supply, commercial execution and combination fighting.”

Complex It refers to custom preparation otherwise branded medicine by a pharmacy or doctor to meet the specific needs of the individual patient. Medications can also agree under other conditions, including when patented drugs are in a short supply. But with the new Nordisk production production and the Wegovy no longer on food and drug administration (FDA) a list of shortagesPharma Giant claims that most complex versions are no longer justified. FDA also said that it could start quoting companies and health professionals who continue to offer certain versions of complex semaglutide Starting on 22. May. New Nordisk lists Wegovy on $ 1,349.02 per month, and drug deficiency rules have enabled layers to sell the product versions at lower prices.

Jørgensen admitted that “significant growth in the United States” seemed to be “influenced by the Wegovy recipes at the beginning of 2025. Years. For example, a tilenyl teleteatric company Hiss & Hers began to offer complex semallutid Last May. The total sales of the company rose 69% last year to 1.5 billion dollars.

One shareholder asked how long it would last that the trend should be reversed, stating the rumors that broken medications could bring as many as 40% of the market of American obesity.

Jørgensen did not provide a certain timeline, but reported on the multiple anti-competitors’ strategy.

Novo Nordisk says that it is deployed a combination of legal actions, providing doctors and incentives for prices. The company sued several layers, launched an advertising campaign for warning a doctor and a patient on the risks approved by the FDA and introduced a new offer only to cash only. Wegovy for $ 499 per month.